Skip to main content

Advertisement

Fig. 6 | BMC Cancer

Fig. 6

From: Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

Fig. 6

a. Dose-response relationship related to NCI CTCAE-motor dysfunction scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively b. Dose-response relationship related to NCI CTCAE-sensory dysfunction scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively c. Dose-response relationship related to the WHO neuropathy scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively 6 d. Dose-response relationship related to cotton wool assessment with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively e. Dose-response relationship related to monofilament assessment with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively

Back to article page